My research uses neurodevelopmental models to investigate how adverse early-life events or drugs of abuse impact on brain neurochemistry and contribute to cognitive and social dysfunction. The group has a track record of successful collaboration on EU and industry-funded projects, evaluating novel serotonergic, cholinergic, dopaminergic and glutamatergic treatments for disorders like schizophrenia, autism and depression. Current group members are working on a variety of exciting projects, from changes to inflammatory biomarkers in patients with schizophrenia to strategies for optimizing nasal delivery of potential therapeutics.